Stephen P. Squinto, EVP, Research & Development at ALEXION PHARMACEUTICALS INC (ALXN), sold 50,000 shares at $101.81 ($5.0M) on 2012-07-09, disclosed to the SEC on 2012-07-11.
Scheduled sale ($5.0M) by EVP, Research & Development under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $100.34 | 44,100 | $4.4M | 88.1% |
| 2 | $100.98 | 4,700 | $475K | 9.5% |
| 3 | $101.81 | 1,200 | $122K | 2.4% |
| Total | $100.44 avg | 50,000 | $5.0M | 100% |
| Filing → |
| SWTX | BUY | 2019-09-19 | $5.0M | — | Filing → |
| ALXN | SELL | 2014-10-28 | $1.1M | — | Filing → |
| ALXN | SELL | 2014-10-07 | $1.7M | — | Filing → |